sublingual tizanidine 12 mg
Protocol C2/5/TZ:MS-05 EXT
Phase 2 small_molecule terminated
Quick answer
sublingual tizanidine 12 mg for Spasticity is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Spasticity
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated